West Pharmaceutical Services (WST) Surges on Raised 2026 Guidance and Q3 Profit

West Pharmaceutical Services Inc. shares climbed 3.3% on November 09, 2026, to reach $413.09, trading near the top of their 52-week range of $223.83 to $438.27. The gain followed third-quarter earnings that surpassed company expectations and prompted management to lift full-year financial projections.

For the third quarter, net sales grew 8.7% year over year to $874.5 million, supported by 11.9% organic revenue growth. Diluted earnings per share jumped 57.3% to $3.02, while adjusted diluted earnings rose 35.7% to $2.66 per share. Operating margin reached 30.6%, up from 20.8% in the prior-year period.

The surge was primarily driven by the Proprietary Products segment, where sales rose 12.6% to $728.8 million. Within that unit, High-Value Product Components advanced 19.7% to $466.7 million, accounting for approximately 53% of total company revenue. In contrast, the West Vantage segment saw revenue slide 7.3% to $145.7 million, with organic sales dropping 6.6%.

Following the results, West increased its full-year 2026 revenue guidance to between $3.41 billion and $3.42 billion, up from a previous band of $3.345 billion to $3.38 billion. Full-year adjusted diluted earnings are now projected at $9.38 to $9.48 per share, compared to the earlier expectation of $8.85 to $9.05. Capital expenditures for 2026 were trimmed to between $215 million and $220 million.

Capital returns also expanded, with the board declaring a fourth-quarter dividend of 26 cents per share on October 19, an 18% increase over the previous quarter. The company bought back $231 million of its shares during the third quarter, lifting nine-month repurchases to $685 million.

Despite the operational gains, valuation metrics have drawn attention. GuruFocus reported that the current price of $413.09 sits 13.1% above its GF Value estimate of $365.17, pointing out a trailing price-to-earnings ratio of 46.3x against a five-year median of 43.1x. Additionally, corporate insiders sold $6.6M worth of shares over the past 12 months with no recorded insider purchases.